Skip to main content
SpringerLink
Log in

Toxicity and quality of life in published clinical trials for advanced lung cancer

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

In every report on incurable disease, clear presentation of toxicity and of quality of life (QoL) is of essential importance. This postulate was assessed on a series of publications on systemic treatment for advanced lung cancer.

Materials and methods

The analysis covered papers on original phase II–IV clinical trials published between 2013 and 2015 and included in the PubMed database.

Results

Selected for analysis were 349 publications on 333 trials with a total of 78.977 patients. Only 33 trials (10%) dealt with small cell lung cancer. Most trials (56.5%) included only information on frequency and grade of specific toxic phenomena and did not provide data on the frequency of any serious toxicity. The ratio between the frequency of any grade ≥ 3 toxicity and response rate was often unfavorable, especially for second-line treatment of non-small cell lung cancer (3.0) and second-line treatment of small cell lung cancer (5.3). Assessment of QoL was mentioned in 68 (20.4%) trials, of which only 46 publications provided adequate data.

Conclusions

A substantial proportion of publications on trials for advanced lung cancer do not offer adequate information for decisions in clinical practice. Presentation of toxicity should include information on the frequency of any serious toxicity. Quality of life should be monitored and reported in every trial of an incurable disease. Simple instruments for the assessment of QoL are strongly recommended, so as to alleviate burden to patients and to staff, avoid bias due to poor compliance and enable clear analysis and presentation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Zwitter M (2017) Endpoints in reports on clinical trials for advanced lung cancer. J Thorac Oncol 12(S1):S749

    Google Scholar 

  2. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E (2015) Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1:1051–1059. https://doi.org/10.1001/jamaoncol.2015.2639

    Article  PubMed  PubMed Central  Google Scholar 

  3. Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S (2012) Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30:4249–4255. https://doi.org/10.1200/JCO.2012.42.5967

    Article  PubMed  Google Scholar 

  4. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Ann Intern Med 152:726–732. https://doi.org/10.7326/0003-4819-152-11-201006010-00232

    Article  PubMed  Google Scholar 

  5. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309:814–822. https://doi.org/10.1001/jama.2013.879

    Article  PubMed  CAS  Google Scholar 

  6. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D (2004) Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141:781–788

    Article  PubMed  Google Scholar 

  7. Mak KS, van Bommel AC, Stowell C, Abrahm JL, Baker M, Baldotto CS, Baldwin DR, Borthwick D, Carbone DP, Chen AB, Fox J, Haswell T, Koczywas M, Kozower BD, Mehran RJ, Schramel FM, Senan S, Stirling RG, van Meerbeeck JP, Wouters MW, Peake MD (2016) Defining a standard set of patient-centred outcomes for lung cancer. Eur Respir J 48:852–860. https://doi.org/10.1183/13993003.02049-2015

    Article  PubMed  PubMed Central  Google Scholar 

  8. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Br Med J 317:771–775

    Article  CAS  Google Scholar 

  9. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D (2012) Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616–1625. https://doi.org/10.1056/NEJMoa1204410

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Seruga B, Templeton AJ, Vera Badillo FE, Ocana A, Amir E, Tannock IF (2016) Under-reporting of harm in clinical trials. Lancet Oncol 17:e209–e219

    Article  PubMed  Google Scholar 

  11. Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915. https://doi.org/10.1200/JCO.2014.57.9334

    Article  PubMed  CAS  Google Scholar 

  12. Novello S, Capelletto E, Cortinovis D, Tiseo M, Galetta D, Valmadre G, Casartelli C, Rapetti SG, Rossi A (2014) Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the “tolerance” to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. Transl Lung Cancer Res 3:173–180. https://doi.org/10.3978/j.issn.2218-6751.2014.06.10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J (2016) The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. Ann Oncol 27:192–198. https://doi.org/10.1093/annonc/mdv485

    Article  PubMed  CAS  Google Scholar 

  14. Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF (2013) Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 24:1238–1244. https://doi.org/10.1093/annonc/mds636

    Article  PubMed  CAS  Google Scholar 

  15. Zhang S, Liang F, Tannock I (2016) Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer 16:392–397

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Kyte D, Ives J, Draper H, Calvert M (2016) Current practices in patient-reported outcome (PRO) data collection in clinical trials: a cross-sectional survey of UK trial staff and management. BMJ Open 6:e012281. https://doi.org/10.1136/bmjopen-2016-012281

    Article  PubMed  PubMed Central  Google Scholar 

  17. Fairclough DL, Peterson HF, Chang V (1998) Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat Med 17:667–677

    Article  PubMed  CAS  Google Scholar 

  18. Schandelmaier S, Conen K, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Meerpohl JJ, Stegert M, Olu KK, Tikkinen KA, Neumann I, Carrasco-Labra A, Faulhaber M, Mulla SM, Mertz D, Akl EA, Sun X, Bassler D, Busse JW, Ferreira-González I, Lamontagne F, Nordmann A, Gloy V, Raatz H, Moja L, Rosenthal R, Ebrahim S, Vandvik PO, Johnston BC, Walter MA, Burnand B, Schwenkglenks M, Hemkens LG, Bucher HC, Guyatt GH, Briel M, Kasenda B (2016) Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol 27:209. https://doi.org/10.1093/annonc/mdv559

    Article  PubMed  CAS  Google Scholar 

  19. Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM, Yang P (2012) Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol 30:1498–1504. https://doi.org/10.1200/JCO.2010.33.4631

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gaertner J, Weingärtner V, Lange S, Hausner E, Gerhardus A, Simon ST, Voltz R, Becker G, Schmacke N (2015) The role of end-of-life issues in the design and reporting of cancer clinical trials: a structured literature review. PLoS One 10:e0136640. https://doi.org/10.1371/journal.pone.0136640

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

Marjeta Jerala and David Ožura from the Library of the Institute of Oncology Ljubljana provided valuable help in retrieving full-length papers for analysis. Sincere thanks to Terry Jackson for language editing.

Author information

Authors and Affiliations

  1. Institute of Oncology, Zaloska 2, 1000, Ljubljana, Slovenia

    Matjaz Zwitter

  2. Medical Faculty, University of Maribor, Taborska 9, 2000, Maribor, Slovenia

    Matjaz Zwitter

Authors
  1. Matjaz Zwitter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matjaz Zwitter.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Electronic supplementary material

ESM 1

(DOCX 94 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zwitter, M. Toxicity and quality of life in published clinical trials for advanced lung cancer. Support Care Cancer 26, 3453–3459 (2018). https://doi.org/10.1007/s00520-018-4214-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-018-4214-1

Keywords

Search

Navigation